Novo Nordisk/$NVO
1D1W1MYTD1Y5YMAX
Capital at risk
About Novo Nordisk
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Ticker
- $NVO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 66,700
- Headquarters
- Bagsvaerd, Denmark
- Website
- www.novonordisk.com
Novo Nordisk Metrics
BasicAdvanced
$191B
10.74
$4.03
0.35
$1.28
1.89%
Price and volume
Market cap
$191B
Beta
0.35
52-week high
$64.16
52-week low
$35.12
Average daily volume
11M
Dividend rate
$1.28
Financial strength
Current ratio
0.873
Quick ratio
0.642
Long term debt to equity
0.55
Total debt to equity
0.633
Dividend payout ratio (TTM)
44.64%
Interest coverage (TTM)
1,566.84%
Profitability
EBITDA (TTM)
26,685.471
Gross margin (TTM)
81.99%
Net profit margin (TTM)
35.35%
Operating margin (TTM)
48.99%
Effective tax rate (TTM)
21.72%
Revenue per employee (TTM)
$759,030
Management effectiveness
Return on assets (TTM)
18.73%
Return on equity (TTM)
59.82%
Valuation
Price to earnings (TTM)
10.743
Price to revenue (TTM)
3.793
Price to book
5.63
Price to tangible book (TTM)
12.57
Price to free cash flow (TTM)
26.15
Free cash flow yield (TTM)
3.82%
Free cash flow per share (TTM)
1.654
Dividend yield (TTM)
2.96%
Forward dividend yield
1.89%
Growth
Revenue change (TTM)
5.61%
Earnings per share change (TTM)
4.98%
3-year revenue growth (CAGR)
17.84%
10-year revenue growth (CAGR)
11.56%
3-year earnings per share growth (CAGR)
20.74%
10-year earnings per share growth (CAGR)
14.01%
3-year dividend per share growth (CAGR)
18.26%
10-year dividend per share growth (CAGR)
9.55%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Analyst projections of the future price of Novo Nordisk stock.
Bulls say / Bears say
Novo Nordisk reported Q2 2026 adjusted sales growth of 7% at constant exchange rates, driven by strong volume growth in its GLP-1 diabetes and obesity therapies (Reuters)
Adjusted operating profit rose 11% at constant exchange rates in Q2 2026, surpassing analyst forecasts and reflecting disciplined cost management alongside robust revenue momentum (Reuters)
European Commission approved Novo Nordisk’s once-daily Wegovy® pill in July 2026 as the first oral GLP-1 weight-loss treatment for the EU, expanding its obesity care franchise and patient reach (Reuters)
Despite raising its full-year outlook, investors were disappointed by a narrow Q2 sales miss for its new Wegovy® pill and a trial setback for its next-generation obesity drug CagriSema, highlighting execution and pipeline risks (Reuters)
Novo Nordisk recorded DKK 6.3 billion in non-cash impairment charges during Q2 2026 related to intangible pipeline assets, including monlunabant, signalling volatility and potential setbacks in its development pipeline (SEC EDGAR)
Sales of Eli Lilly’s Zepbound and Mounjaro injectables soared in Q2 2026, widening the market share gap with Novo Nordisk and underscoring intensifying competition from tirzepatide-based therapies (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Upcoming events
No upcoming events
Novo Nordisk News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.